- Chromosome 18 Deletion Syndrome
- Diastrophic Dysplasia
- Diamond Blackfan Anemia
- Chorioretinal Atrophy- Progressive …
- Pendred Syndrome
- Osteosclerosis Autosomal Dominant Worth …
- Noninsulin-dependent Diabetes Mellitus …
- Shapiro Syndrome
- Severe Achondroplasia With …
- Mitral Valve Prolapse- Familial- X- …
- Waardenburg Syndrome Type 1
- Parkinson Disease- Juvenile- Autosomal …
Thymic epithelial tumorA prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
J Thorac Oncol. 2013 Jul;8(7):959-66
Authors: Park S, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K
BACKGROUND: Initial complete resection is a powerful prognostic indicator of survival in thymic epithelial tumors (TETs), but is obviously related to tumor stage. Here, we report the results of a prospective study of neoadjuvant docetaxel/cisplatin in locally advanced TETs.
METHODS: Patients with histologically proven, Masaoka stage III/IV TETs at presentation were enrolled in this open-label, phase II, nonrandomized study. Patients received docetaxel 75 mg/m² I.V, followed by cisplatin 75 mg/m² I.V on day 1 of every 3-week cycle. After three cycles, surgical resection was performed if the tumor was considered resectable.
RESULTS: From March 2007 to July 2011, 27 patients were enrolled in the trial. Masaoka stage at presentation was III (n = 8; 29.6%), IVA (n = 17; 63.0%), and IVB (n = 2; 7.4%). Histologic types were nine thymomas (33.3%) and 18 thymic carcinomas (66.7%). After completion of neoadjuvant chemotherapy, 17 patients (63.0%) achieved partial response and 10 (37.0%) had stable disease. Nineteen patients (70.4%) underwent surgery and eight did not because of surgeons' decision (n = 5), patient refusal (n = 2), or decision to undergo radiation therapy instead (n = 1). Fifteen among the 19 patients achieved complete resection (78.9%), which yields 55.6% of complete resection rate with intent-to-treat analysis. The most common side effects of severity greater than grade 3 were neutropenia and diarrhea. With a median follow-up of 42.6 months, 4-year overall survival, and progression-free survival in all patients was 79.4 and 40.6%, respectively.
CONCLUSION: Neoadjuvant docetaxel/cisplatin is both feasible and well tolerated, and potentially improves surgical resectability in patients with advanced TETs.
PMID: 23722169 [PubMed - indexed for MEDLINE]